Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × 68Ga-pentixafor × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Lymphoma 2 Thymoma 1 Neuroendocrine Tumors 1 Lymphoma, Non-Hodgkin 1 Leukemia 1 Histiocytosis, Sinus 1 Erdheim-Chester Disease 1

Interventions

Cyclophosphamide 6 pembrolizumab 5 Cisplatin 5 Carboplatin 5 Sunitinib 4 Paclitaxel 4 Radiotherapy 3 130-nm albumin-bound paclitaxel 3 selinexor 2 Thymectomy 2 Taxes 2 Robotic Surgical Procedures 2 Ramucirumab 2 Prednisone 2 Pemetrexed 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Imatinib Mesylate 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2 Chemoradiotherapy 2 Celecoxib 2 zimberelimab 1 regorafenib 1 olaparib 1 lenvatinib 1 fludarabine 1 epacadostat 1 entinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06086327 2023-10-17

Application of 68Ga-Pentixafor PET/CT for Thymoma

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Unknown

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡